Impaired antibody responses were observed in patients with type 2 diabetes mellitus after receiving the inactivated COVID-19 vaccines

• Published in: Virology journal 2023-02, Vol.20 (1), p.22-22, Article 22
• Main Authors: Xiang, Feng, Long, Boyu, He, Jiaoxia, Cheng, Feifei, Zhang, Sijing, Liu, Qing, Chen, Zhiwei, Li, Hu, Chen, Min, Peng, Mingli, Yin, Wenwei, Liu, Dongfang, Ren, Hong
• Format: Article
• Language: English
• Subjects: Adverse events; Antibodies; Antibodies, Neutralizing; Antibodies, Viral; Antibody Formation; Antibody responses; Beta cells; Blood; Body mass index; Case-Control Studies; Cell-mediated immunity; Clinical trials; Coronaviruses; COVID-19 - prevention & control; COVID-19 vaccines; COVID-19 Vaccines - adverse effects; Diabetes; Diabetes mellitus (non-insulin dependent); Diabetes Mellitus, Type 2; Disease; Epidemics; Humans; Immunoglobulin G; Immunological memory; Insulin; Memory B cells; Memory cells; Pneumonia; Safety; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Type 2 diabetes mellitus; Vaccines, Inactivated
• ISSN: 1743-422X; 1743-422X
• DOI: 10.1186/s12985-023-01983-7

Patients with type 2 diabetes mellitus (T2DM) have been reported to be more susceptible to 2019 novel coronavirus (2019-nCoV) and more likely to develop severe pneumonia. However, the safety and immunological responses of T2DM patients after receiving the inactivated vaccines are not quite definite. Therefore, we aimed to explore the safety, antibody responses, and B-cell immunity of T2DM patients who were vaccinated with inactivated coronavirus disease 2019 (COVID-19) vaccines. Eighty-nine patients with T2DM and 100 healthy controls (HCs) were enrolled, all of whom had received two doses of full-course inactivated vaccines. At 21-105 days after full-course vaccines: first, the safety of the vaccines was assessed by questionnaires; second, the titers of anti-receptor binding domain IgG (anti-RBD-IgG) and neutralizing antibodies (NAbs) were measured; third, we detected the frequency of RBD-specific memory B cells (RBD-specific MBCs) to explore the cellular immunity of T2DM patients. The overall incidence of adverse events was similar between T2DM patients and HCs, and no serious adverse events were recorded in either group. Compared with HCs, significantly lower titers of anti-RBD-IgG (p = 0.004) and NAbs (p = 0.013) were observed in T2DM patients. Moreover, the frequency of RBD-specific MBCs was lower in T2DM patients than in HCs (p = 0.027). Among the 89 T2DM patients, individuals with lower body mass index (BMI) had higher antibody titers (anti-RBD-IgG: p = 0.009; NAbs: p = 0.084). Furthermore, we found that sex, BMI, and days after vaccination were correlated with antibody titers. Inactivated COVID-19 vaccines were safe in patients with T2DM, but the antibody responses and memory B-cell responses were significantly decreased compared to HCs. NCT05043246. September 14, 2021. (Clinical Trials.gov).